Immunome Inc
IMNM
View Detailed Chart
24.880USD
+0.880+3.67%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.28BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+3.67%
5 Days
+1.06%
1 Month
+24.52%
6 Months
+152.08%
Year to Date
+15.83%
1 Year
+128.89%
View Detailed Chart
TradingKey Stock Score of Immunome Inc
Currency: USD Updated: 2026-02-06Key Insights
Immunome Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.45.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Immunome Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Immunome Inc Highlights
StrengthsRisks
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.04M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.04M.
Undervalued
The company’s latest PE is -8.41, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 93.24M shares, increasing 6.55% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 202.30K shares of this stock.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
34.455
Target Price
+30.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Immunome Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Immunome Inc Info
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Ticker SymbolIMNM
CompanyImmunome Inc
CEOSiegall (Clay B)
Websitehttps://immunome.com/
Related Instruments
+3.63%
+3.17%
+0.93%
+1.99%
+1.78%
+1.53%
-0.96%
+4.49%
+2.10%
+10.00%
+2.72%
+4.07%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69205.000
-396.180 (-0.57%)
282.580
+22.390 (+8.61%)
2081.780
-21.040 (-1.00%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
